A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of
ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and
anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.